Smith & Nephew Stock Rating Reaffirmed by JPMorgan Chase & Co. (SN)
Smith & Nephew (LON:SN)‘s stock had its “neutral” rating restated by JPMorgan Chase & Co. in a research note issued on Friday, Stock Ratings Network reports.
A number of other firms have also recently commented on SN. Analysts at Deutsche Bank reiterated a “hold” rating on shares of Smith & Nephew in a research note to investors on Thursday. They now have a GBX 650 ($10.67) price target on the stock. Separately, analysts at Galvan Research reiterated a “buy” rating on shares of Smith & Nephew in a research note to investors on Wednesday. They now have a GBX 930 ($15.27) price target on the stock. Finally, analysts at Goldman Sachs Group Inc. downgraded shares of Smith & Nephew to a “sell” rating in a research note to investors on Wednesday. They now have a GBX 720 ($11.82) price target on the stock, down previously from GBX 780 ($12.80). Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and five have issued a buy rating to the company’s stock. Smith & Nephew has an average rating of “Hold” and a consensus price target of GBX 811 ($13.31).
Smith & Nephew (LON:SN) traded down 1.45% on Friday, hitting GBX 883.00. 2,125,208 shares of the company’s stock traded hands. Smith & Nephew has a 52 week low of GBX 692.592 and a 52 week high of GBX 888.00. The stock’s 50-day moving average is GBX 861.7 and its 200-day moving average is GBX 805.. The company’s market cap is £7.938 billion.
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.